| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | bid1870 | gCSI | pan-cancer | AAC | -0.11 | 0.06 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.061 | 0.06 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | 0.059 | 0.06 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | 0.081 | 0.06 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.066 | 0.06 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.07 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | 0.065 | 0.07 |
| mRNA | SCH-529074 | CTRPv2 | pan-cancer | AAC | -0.066 | 0.07 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.07 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.07 |